New York, New York–(Newsfile Corp. – January 4, 2025) Bleichmar Font & Auld LLP announces research on BioAge Labs, Inc. (NASDAQ: BIOA) due to violations of federal securities laws.
If you have invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Why is BioAge being researched?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases, with a particular focus on obesity. The company's lead product candidate, azelaprag, is an orally available small apelin receptor (APJ) agonist, designed to enhance weight loss.
At the time, the company said that azelaprag was well tolerated in 265 people in a Phase 1 clinical trial and that after the IPO the company was “well equipped to advance our clinical programs(.)”
The stock drops as the Truth is revealed
On December 6, 2024, BioAge announced that it had stopped the STRIDES Phase 2 trial of azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. The company said the decision to stop the STRIDES Phase 2 study of azelaprag “was made clear” due to the “emerging safety profile of the current doses tested (.)”
This news caused the company's stock price to drop more than 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.
Click here for more information: https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
What can you do?
If you have invested in BioAge you have legal options and are encouraged to submit your information to the firm.
All representations are subject to a contingency fee, at no cost to you. Shareholders are not responsible for any court costs or litigation costs. The firm will seek court approval for any fees and costs incurred.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Why Bleichmar Font and Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiffs law firms by ISS SCAS in 2023 and its attorneys were named Titans of the Plaintiffs Bar by Law360 and Top Attorneys by Thompson Reuters. Among its most recent notable achievements, BFA returned more than $900 million in value to Tesla (NASDAQ: ), Inc.'s Board of Directors. (pending court approval), and $420 million in Teva Pharmaceutical (NYSE: ) Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Marketing lawyer. Past results do not guarantee future results.
To view the source of this document, please visit https://www.newsfilecorp.com/release/235856